Enzalutamide-ADT Cuts Risk for Disease Spread in Nonmetastatic Prostate Cancer
CHICAGO — Combining enzalutamide (Xtandi) with an androgen deprivation therapy (ADT) boosted metastasis-free survival (MFS) in patients with prostate cancer at high risk for biochemical recurrence, according to the EMBARK trial. After a median follow up of 60.7 months, the combination of enzalutamide and leuprolide acetate ADT demonstrated a 58% reduction in the risk of […]
Adding Talazoparib to Enzalutamide Boosts PFS in Metastatic Prostate Cancer
SAN FRANCISCO — Treatment with the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) significantly improved radiographic progression-free survival (rPFS) compared with enzalutamide plus placebo in patients with metastatic castration-resistant prostate cancer (mCRPC), the phase III TALAPRO-2 trial showed. Among 805 randomized patients, rPFS assessed by blinded independent central review was not reached in those who […]
Xtandi During AS Reduced Progression Risk in Early Prostate Cancer
Patients with low- or intermediate-risk localized prostate cancer who received enzalutamide (Xtandi) monotherapy saw a reduced risk of cancer progression, according to a randomized phase II trial. Among 227 patients on active surveillance (AS), treatment with enzalutamide reduced the risk of pathological or therapeutic prostate cancer progression by 46% compared with AS alone (HR 0.54, […]
Another Link Between Prostate Cancer Hormone Tx and Impaired Cognition
Hormonal therapy for advanced prostate cancer, particularly enzalutamide (Xtandi), had a significant association with cognitive impairment, an analysis of a large drug-safety database showed. Traditional hormonal therapy increased the odds of cognitive impairment by 47% versus men who did not receive the therapy. The odds more than doubled among men who received novel androgen receptor […]